| # | Website | Score in June 2020 | 1m changes |
|---|
| 1 | Building the Chronology of Early Chinese History | 2 | 0 |
| 2 | Expansion and Contraction Patterns of Large Polities: Context for Russia | 2 | 0 |
| 3 | An Apocalypse Think Tank | 1 | 0 |
| 4 | Genomic Divergences between Humans and Other Hominoids and the Effective Population Size of the Common Ancestor of Humans and Chimpanzees | 1 | 0 |
| 5 | What makes a modern human | 1 | 0 |
| 6 | Biomes and human distribution during the last ice age | 1 | 0 |
| 7 | The Kingdom of Kush: An African Centre on the Periphery of the Bronze Age World System | 1 | 0 |
| 8 | 10.1093/qjmed/hcl076 | 1 | 0 |
| 9 | Art in Ancient Ife, Birthplace of the Yoruba | 1 | 0 |
| 10 | XXIV. Note on the theory of the greenhouse | 1 | 0 |
| 11 | 10.1038/scientificamerican0116-58 | 1 | 0 |
| 12 | Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries | 0 | 0 |
| 13 | Response to Malaria Epidemics in Africa | 0 | 0 |
| 14 | Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria | 0 | 0 |
| 15 | Laboratory diagnosis of malaria in nonhuman primates | 0 | 0 |
| 16 | Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination | 0 | 0 |
| 17 | Spread of Artemisinin Resistance in Plasmodium falciparum Malaria | 0 | 0 |
| 18 | Anopheles gambiaeGenome: Completing the Malaria Triad | 0 | 0 |
| 19 | Malaria zoonoses | 0 | 0 |
| 20 | Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria | 0 | 0 |
| 21 | Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence | 0 | 0 |
| 22 | CLINICAL ASPECTS OF UNCOMPLICATED AND SEVERE MALARIA | 0 | 0 |
| 23 | Redefining cerebral malaria by including malaria retinopathy | 0 | 0 |
| 24 | The therapeutic potential of metal-based antimalarial agents: Implications for the mechanism of action | 0 | 0 |
| 25 | Malaria Primer for Clinicians in the United States | 0 | 0 |
| 26 | Substandard medicines in resource-poor settings: a problem that can no longer be ignored | 0 | 0 |
| 27 | Plasmodium knowlesi:Finally Being Recognized | 0 | 0 |
| 28 | Plasmodium knowlesi: A Malaria Parasite of Monkeys and Humans | 0 | 0 |
| 29 | The cellular and molecular basis for malaria parasite invasion of the human red blood cell | 0 | 0 |
| 30 | History of Human Parasitology | 0 | 0 |
| 31 | Advances and challenges in malaria vaccine development | 0 | 0 |
| 32 | Malaria in the Greater Mekong Subregion: Heterogeneity and complexity | 0 | 0 |
| 33 | Artemisinin resistance: current status and scenarios for containment | 0 | 0 |
| 34 | Thiamin (Vitamin B1) Biosynthesis and Regulation: A Rich Source of Antimicrobial Drug Targets? | 0 | 0 |
| 35 | Electronic mosquito repellents for preventing mosquito bites and malaria infection | 0 | 0 |
| 36 | Malaria Management: Past, Present, and Future | 0 | 0 |
| 37 | Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications | 0 | 0 |
| 38 | Shrinking the malaria map: progress and prospects | 0 | 0 |
| 39 | The ’hidden’ burden of malaria: cognitive impairment following infection | 0 | 0 |
| 40 | Chemoprophylaxis in malaria: drugs, evidence of efficacy and costs | 0 | 0 |
| 41 | Malaria Prevention in Short-Term Travelers | 0 | 0 |
| 42 | A new world malaria map: Plasmodium falciparum endemicity in 2010 | 0 | 0 |
| 43 | Vaccines for preventing malaria (SPf66) | 0 | 0 |
| 44 | Malaria in 2002 | 0 | 0 |
| 45 | Spurious and counterfeit drugs: a growing industry in the developing world | 0 | 0 |
| 46 | Vaccines for preventing malaria (blood-stage) | 0 | 0 |
| 47 | Malaria | 0 | 0 |
| 48 | Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project | 0 | 0 |
| 49 | The Changing Disease-Scape in the Third Epidemiological Transition | 0 | 0 |
| 50 | The impact of maternal malaria on newborns | 0 | 0 |
| 51 | Estimating the Global Clinical Burden of Plasmodium falciparum Malaria in 2007 | 0 | 0 |
| 52 | Population genetics of malaria resistance in humans | 0 | 0 |
| 53 | Vaccines against malaria | 0 | 0 |
| 54 | Technologies for global health | 0 | 0 |
| 55 | Reflections on the ’discovery’ of the antimalarial qinghao | 0 | 0 |
| 56 | Cerebral Malaria: Mechanisms of Brain Injury and Strategies for Improved Neurocognitive Outcome | 0 | 0 |
| 57 | Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite | 0 | 0 |
| 58 | Drugs for preventing malaria in travellers | 0 | 0 |
| 59 | Malaria, Plasmodium falciparum and its apicoplast | 0 | 0 |
| 60 | Systematic review and meta-analysis: rapid diagnostic tests versus placental histology, microscopy and PCR for malaria in pregnant women | 0 | 0 |
| 61 | The Quest for Quinine: Those Who Won the Battles and Those Who Won the War | 0 | 0 |
| 62 | Dihydroartemisinin/Piperaquine | 0 | 0 |
| 63 | Eradication of Anopheles gambiae from Brazil: lessons for malaria control in Africa? | 0 | 0 |
| 64 | Ongoing challenges in the management of malaria | 0 | 0 |
| 65 | Malaria Attributable to the HIV-1 Epidemic, Sub-Saharan Africa | 0 | 0 |
| 66 | How Malaria Has Affected the Human Genome and What Human Genetics Can Teach Us about Malaria | 0 | 0 |
| 67 | Discoverers of quinine | 0 | 0 |
| 68 | Malaria in adolescence: burden of disease, consequences, and opportunities for intervention | 0 | 0 |
| 69 | Global malaria mortality between 1980 and 2010: a systematic analysis | 0 | 0 |
| 70 | Ecology and conservation biology of avian malaria | 0 | 0 |
| 71 | Insecticide-treated bed nets and curtains for preventing malaria | 0 | 0 |
| 72 | Counterfeit and substandard antimalarial drugs in Cambodia | 0 | 0 |
| 73 | The use of remotely sensed environmental data in the study of malaria | 0 | 0 |
| 74 | A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy | 0 | 0 |
| 75 | Molecular interactions in the placenta during malaria infection | 0 | 0 |
| 76 | Intermittent preventive treatment for malaria in children living in areas with seasonal transmission | 0 | 0 |
| 77 | Antipyretic measures for treating fever in malaria | 0 | 0 |
| 78 | Estimating the Number of Insecticide-Treated Nets Required by African Households to Reach Continent-wide Malaria Coverage Targets | 0 | 0 |
| 79 | Transgenic RodentPlasmodium bergheiParasites as Tools for Assessment of Functional Immunogenicity and Optimization of Human Malaria Vaccines | 0 | 0 |
| 80 | Plasmodium malariae and Plasmodium ovale – the ‘bashful’ malaria parasites | 0 | 0 |
| 81 | Vitamin B metabolism in Plasmodium falciparum as a source of drug targets | 0 | 0 |
| 82 | Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa | 0 | 0 |
| 83 | Counterfeit anti-infective drugs | 0 | 0 |
| 84 | A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia | 0 | 0 |
| 85 | Insecticide-treated net coverage in Africa: mapping progress in 2000–07 | 0 | 0 |
| 86 | Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum | 0 | 0 |
| 87 | Management of Severe Malaria: Results from Recent Trials | 0 | 0 |
| 88 | Transfusion‐Transmitted Malaria in Countries Where Malaria Is Endemic: A Review of the Literature from Sub‐Saharan Africa | 0 | 0 |
| 89 | WHO combats counterfeit malaria drugs in Asia | 0 | 0 |
| 90 | MOSQUITO BEHAVIOR AND VECTOR CONTROL | 0 | 0 |
| 91 | Working without a blindfold: the critical role of diagnostics in malaria control | 0 | 0 |
| 92 | Indoor residual spraying for preventing malaria | 0 | 0 |
| 93 | A Fresh Look at the Origin of Plasmodium falciparum, the Most Malignant Malaria Agent | 0 | 0 |
| 94 | Malaria vector control: from past to future | 0 | 0 |
| 95 | Cerebral malaria | 0 | 0 |
| 96 | SOCIAL IMPLICATIONS OF MALARIA AND THEIR RELATIONSHIPS WITH POVERTY | 0 | 0 |
| 97 | What is the evidence for the existence of Plasmodium ovale hypnozoites? | 0 | 0 |
| 98 | Malaria in pregnancy in the Asia-Pacific region | 0 | 0 |
| 99 | Immune mechanisms in malaria: new insights in vaccine development | 0 | 0 |
| 100 | Ferrocene-based antimalarials | 0 | 0 |
| 101 | Costs and financial feasibility of malaria elimination | 0 | 0 |
| 102 | The economic and social burden of malaria | 0 | 0 |
| 103 | Malaria and Rome | 0 | 0 |
| 104 | Critical Care Aspects of Malaria | 0 | 0 |
| 105 | Artesunate versus quinine for treating severe malaria | 0 | 0 |
| 106 | Challenges of drug-resistant malaria | 0 | 0 |
| 107 | Respiratory Manifestations of Malaria | 0 | 0 |
| 108 | The Plasmodium falciparum-infected red blood cell | 0 | 0 |
| 109 | Clinical review: Severe malaria | 0 | 0 |
| 110 | Systems immunology of human malaria | 0 | 0 |
| 111 | Drug Resistance in Plasmodium: Natural Products in the Fight Against Malaria | 0 | 0 |
| 112 | Mosquito larval source management for controlling malaria | 0 | 0 |
| 113 | Global Status of DDT and Its Alternatives for Use in Vector Control to Prevent Disease | 0 | 0 |
| 114 | Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond | 0 | 0 |
| 115 | Malaria Parasite Pre-Erythrocytic Stage Infection: Gliding and Hiding | 0 | 0 |
| 116 | The Forgotten Malaria | 0 | 0 |
| 117 | Genetic variation and susceptibility to infection: the red cell and malaria | 0 | 0 |
| 118 | Qinghaosu (Artemisinin): The Price of Success | 0 | 0 |
| 119 | Determinants of relapse periodicity in Plasmodium vivax malaria | 0 | 0 |
| 120 | Malaria Eradication in the United States | 0 | 0 |
| 121 | Malaria Rapid Diagnostic Tests | 0 | 0 |
| 122 | Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border | 0 | 0 |
| 123 | Is malaria a disease of poverty? A review of the literature | 0 | 0 |